

EXHIBIT 7: AUROBINDO SEARCH TERM LIST

AUROBINDO SEARCH TERMS AND SEARCH PROCEDURE

(*23084* or *203081* or *203630* or *204774*)
EIR or "establishment inspection report"
OAI or "official action indicated"
"voluntary action indicated"
*diethylamine or "*diethyl amine"
*dimethylamine or "*dimethyl amine"
(*dimethylformamide or DMF) AND (<Drug Name>)
*dimethylmethanamide
ghost
NDEA
NDMA
nitra
nitrite
nitrosa
nitroso
NMBA (deferred to after JPML decision)
trosomine
(Form483) or (Form /3 483) or (483 /3 letter) or (483 /3 warn*) or (704 pre/3 b)
C2H6N2O or "(CH3)2NN=O" or "CH32NN=O" or "(CH3)2NC(O)H" or CH32NCOH or C3H7NO or "(CH3CH2)2NH" or CH3CH22NH or C4H11N or "(CH3)2NH" or CH32NH or
carcin*
deviat* /5 cancer* or deviat* /5 toxic or or deviat* /5 hazard* or deviat* /5 fatal
FDA /10 warning
gene* /3 mutat*
genotoxic*
solvent /5 cancer* or solvent /5 toxic or or solvent /5 hazard* or solvent /5 fatal
solvent* /5 contamin*
(test* /5 canc*) AND (<Drug Name> OR (<Solvents> AND NOT <other drug names>))
tetrazol*

<term> (no modifiers)^

^Except if run against custodians in management over more than one facility, in which case to be run as indicated in agreed to procedure.

Last Name	First Name
Agrawal	Atul
Akhtar	Saleem
Amin	Pankaj
Arasu	
Arista	
Arroyo	
Baker	Peter
Barreto	
Barrowcliff	
Bellamy	
Bernard	Tonia
Bizjak	
Boyd	Justin
Bretz	Paula
Brown	Darren
Cartwright	
Casale	
Chapman	Johnathan
Charity	Antony
Chester	Bonita
Clausen	
Cosgrove	
Cruz	
Dezan	
Dickinson	Gwyn
Dobbin	
Dombrowski	
Donald	Steven
Dong	Eric
Eban	
Ernst	
Estrella	Maria
Etminan	
Ford	Susanna
Frazier	Laurie
Gavini	
George	Jogy

Last Name Standalone UNLESS IF First Name Exists, THEN (Last Name /3 First Name) OR (Last Name AND <Regulatory Modifiers>)

Ghoshal	Rabin
Gidado	
Goga	
Goga	Michael
Hall	Patrice
Hallas	
Harouaka	
Hebert or Della or Dellareese	
Hicks	Kellia
Higgins	Brooke
Huaren	
Hustedt	
Johansen	
Jones	Latoria
Karapetyan*	
Khan	Farhana
Khurana	Sangeeta
Kristensen	
Lopez Rubet	
Maldonado	
Mankind	
Mansournia	
Marcisin	
Martinez	Miguel
Mason	James
Mathew or Mathews	Lata
Mayasandra	Pal
Melende	
Min	Ko
Mistler	
Motamed	
Motta	
Mueller	
Narula	
Navas	
Nguyen	Truong
Oladimeji	
Panicker	
Patel	Nayan
Philopoulos	
Pitts	Simone
Podaralla	Satheesk
Pottgard	
Priester	
Pyramides	
Quartarolo	
Ray	Marcus

Razzaghi	Frederick
Roberts	Daniel
Roy	Melissa
Schwartz	Paul
Shah	Dipesh
Skanchy	
Srivasta	
Srivastava	Rajiv
Stieg	
Sweeney	
Szestypalow	
Tomasso	
Ulysse	
Upadhyay	Pratik
Verdel	
Wakijira	Chaltu
Wang	Zhao
Warnick	
Xu	Atul
Young	Rochelle
Yuscus	
Zaklady	
Zamil	
Zamperini	
Zhen Zhou	

("adverse event*" or AER) and (<drug name> or <solvents> or <facility names>)
"changes being effected"
"prior approval supplement"
adulterat*
alert*
CAPA or corrective pre/3 "preventive action"
CFR or eCFR or "code of federal regulations" or USC or "United States"
Citizen* pre/3 Petition
(Establishment pre/3 Inspection)
import* /3 (ban or alert or restrict*)
inadequat*
inspect*
investigat*
major /3 change
(master /3 file) and (<drug name> or
minor /3 change
moderate /3 change
Monthly /3 update
(official pre/3 action* /4 indicat*)
observation*
OOS or "out of spec*" or "out-of-spec"
OOT or "out-of-trend" or "out of trend"
PADER* and (<drug name> or
<solvents> or <facility names>)
VAI or (voluntary pre/3 action* /4 indicat*)
violat*
warn*

<Term> AND (<Drug Name> OR (<Solvents> AND NOT <other drug names>) OR <regulatory modifiers> OR <facility names>)

(bottle pre/2 lies) or Eban
bury or burie* or conceal*
cGMP* or (current pre/5 manufacturing) or GMP*
"cover up*" or coverup* or "cover-up"
crash* or disaster*
data /4 integrity or data /4 reliabl*
delet* or destroy* or remov* or trash* or
hide* or suppress*
whistleblow*

**<Term> AND (<Drug
Name> OR (<Solvents>
AND NOT <other drug
names>) OR <regulatory
modifiers> OR <inspect>
OR <manufacturing
modifiers> OR <medical
modifiers> OR <facility
names>)**

"anion-exchange" or anionexchange or "anion exchange"
"ion-exchange" or ionexchange or "ion exchange"
PCRC
aberran*
abnorm*
ALS
bioequiv*
CAPA or corrective pre/5 action
Chromato*
complain*
contami*
degradant* or impurit*
detect*
EI-MS or EL-MS or "electron ionization"
elude*
fail*
fatal*
GC or "GC-FID" or GCMS or "GC-MS"
hazard*
headspace
heat
HPLC-UV
HS
incomplet* /5 data*
LCMS
mass spectro*
method /5 qualification
noise*
noti* w/5 pharm*
obscure*
observation*
peak*
press /4 release
preventative /5 action
problem*
puri*
quality
recall*
repe* /4 error*
residu*
retrospec*
risk*
signal*
spectro*
spike*
suitab*

<Term> AND (<Drug Name> OR (<Solvents> AND NOT <other drug names>) OR <manufacturing modifiers>)

toxic*
unknown* or unk or unks
validat*

“IC Route” or “IC process” OR “IC-Route” OR “IC-Process” or “I-C” or “I-B” or “IB Route” or “IB Process” or “IB-Process” or “IB-Route”
assay*
assessment*
batch /5 records
biocompat*
byproduct*
CAPA or corrective pre/3 "preventive action"
certificat*
change* /3 control*
change* /5 process*
COA or certificat* pre/3 analys*
concentra*
condensa*
conversion*
critical /4 change
crude*
deviat*
diastereo*
discrepanc*
error*
esterficat*
expir*
formaldehyde
malfunct*
material* /3 loss*
moiety or moieties
process /5 change
quench*
reagent*
reclaim*
recover*
recycl*
repack* or "re-pack*"
resal*
resell*
reuse*
ring*
solvent*
suppress*
TEA or Triethyl*
temperature

<Term> AND (<Drug Name> OR (<Solvents> AND NOT <other drug names>))

TIN or Tributyl*
yield*

bladder*
blood*
cancer* or precancer* or pre-cancer*
colon*
death* or dead or fatal
esophag*
gastro*
intestin*
kidn* or renal*
laten*
leukemia*
liver*
lymphoma*
muta*
myeloma*
NHL or non-hodgkin*
toxicolog*
onset*
oncolog*
ovar*
pancrea*
prostate*
stomach*

**<Term> AND (<Drug
Name> OR (<Solvents>
AND NOT <other drug
names>))**

best /3 pric*
bulk /3 suppl*
impairment
IRR
manufactur* /3 cost*
marginal /5 cost*
market* /5 share*
net /5 profit*
net /5 valu*
NPA
NPV
rate /10 return
rebate*
sourc* w/5 agree* or sourc* w/5 anal* or sourc* w/5 contract* or sourc* w/5 forecast* or sourc* w/5 plan* or sourc* w/5 strat*
suppl* w/5 agree* or suppl* w/5 anal* or suppl* w/5 contract* or suppl* w/5 forecast* or suppl* w/5 plan* or suppl* w/5
SWOT or (strength pre/7 threat*)
writ* pre/5 off
(average or avg) AND (pric* or cost* or margin* or profit* or revenue*)
(avg) AND (pric* or cost* or margin* or profit* or revenue*)
(contract) AND (distrib* or PBM)
(cost*) AND (analy* or forecast* or plan* or strat*)
(operat* w/5 margin*) AND (margin* or pric*) AND (decreas* or increas* or list* or strat* or expect* or project*)
(recall) AND (loss or impairm* or write* or reimburs* or indemn* or charg* or
(sales) /5 (expect* or project*)
(var*) /5 (cost*)
(variable) /5 (cost*)

**<Term> AND (<Drug
Name> OR (<Solvents>
AND NOT <other drug
names>))**

Alembic
ABDC or Amerisource* or "American Health Packaging" or AHP
Amerigen
ANDA
Auro* or APL or APUSA
boehringer ingelheim
Bristol
Camber
Cobalt
distribut*
Forest
Hetero
Huahai
Indoco
Ivax
Jubilant
Lantech*
Macleod*
Matrix
Mylan
Novartis
Par
Princeton
Qualanex
Ranbaxy
Sandoz
Syncore
Synthon
Teva
Torrent
Unichem
Watson
Zhejiang*
ZHP

<Term> AND (<Drug Name> OR (<Solvents> AND NOT <other drug names>))

Irbesartan*
Avapro*
Aprovel*
Avalide*
HCT or HCTZ
Sartan or sartans

<drug names modifiers>

“sodium azide*”
formaldehyde
-N3
xylene
acid*
aqueous*
chloramin*
HNO2
hydrochlor*
N-3*
NaNO*
“sodium nitrite*”
tolue*
Tributyl* or TIN
Triethyl* or TEA or “tri ethyl*” or “tri-ethyl*”
zinc /3 chloride
ZnCl*

<solvents modifiers>

"Abbreviated New Drug Application" or ANDA
CDC or "Centers for Disease Control"
CDER or "Center for Drug Evaluation and Research"
DEA or "Drug Enforcement Administration" or "Drug Enforcement Agency"
"Environmental Protection Agency" or EPA or USEPA or "US-EPA" or "1200 Pennsylvania"
"Food and Drug Administration" or FDA or USFDA or "US-FDA" or "College Park"
NIH or "National Institutes of Health"

<regulatory modifiers>

Agency
inspect
regulat

<inspect modifiers>

backup /3 data
impurit* and degradant*
recall*
residu*
solvent*
spike*
test*
unknown /3 peak or unknown /3 spike or unknown /3 impurit* or unknown /3 contamin*

<manufacturing modifiers>

"adverse event*" or AER*
bladder*
blood*
cancer* or precancer* or pre-cancer*
colon*
death* or dead or fatal
esophag*
gastro*
intestin*
kidn* or renal*
laten*
leukemia*
liver*
lymphoma*
MedWatch* or "Safety Information and Adverse Event Reporting"
muta*
myeloma*
NHL or non-hodgkin*
toxicolog*
onset*
oncolog*
ovar*
PADER*
pancrea*
prostate*
stomach*

**<medical conditions
modifiers>**

analys*
cost*
decreas*
distrib*
expect*
gross
impairm*
increas*
indem*
list*
loss*
margin*
market*
net
PBM
plan
pric*
profit*
project*
recall*
revenue*
share*
stock*
strat*
write*

<economic modifiers>

“Unit 1” or “Unit I” or “Unit-1” or “Unit-I” or
3004021253

“Unit 9” or “Unit IX” or “Unit-9” or “Unit-IX”
or *3006370489*

<facility names modifiers>

ABPI
AEMPS
Agency /3 Therapeutic
AIFA
ALIMS
ANMAT
BDA
BfArM
"British Pharmaceutical Industry"
"Bulgarian Drug Agency"
Canad* /3 Health
"Central drugs standard control"
CEP
DKMA
EMA
European /3 medic*
"European Medical"
Fimea
"Health Canada"
Health* /5 Agency
Hong Kong /7 "Drug Office"
HPRA
IMA
MEB
Medical /4 agency
"Medical Products Agency"
MFDS
MHRA
Ministry /3 Health
Ministry /5 drug
MPA
NAMMD
NHS
NIHS
NoMA
NPRA
OGYEI
PHARMAC
SAMLV
SAMR
SCMA
SIDC
"State Administration for Market"
SUKL
Swissmedic

**<foreign regulatory agency
modifiers>**

Foreign Regulatory Agencies

Figure 8-006

TGA
"Therapeutic Goods Administration"

SEARCH TERMS PROCEDURE

1. Search Terms

The Primary Search Terms and Modifiers lists given above shall be used for searching of custodial records subject to the procedure set forth herein.

As there are several custodians who will be included in irbesartan discovery who were already custodians during valsartan discovery, the procedure for running terms for them will differ from those employees who are first-time irbesartan custodians. Those custodians whose files were produced during the valsartan portion of the case shall be referred to as the “Original Custodians.” The Parties disagree on the scope of the Relevant Time Period and will submit their disagreement to the Court for resolution by September 8, 2023. After resolution by the Court, for the Original Custodians, Aurobindo will top up the custodial files to reflect the Relevant Time Period as ordered.

Aurobindo will then run the new set of search terms over the Original Custodians’ files, deduplicate documents for those which have already been produced, and produce any previously unproduced files. To the extent a duplicate document is not produced but is located in the custodial file of a different custodian, Aurobindo will produce an overlay production that adds those custodians to the metadata for the documents at issue.

For the new custodians, the search will be run in full in accordance with the agreed upon set of search terms in this document.

For all search terms—and as described below in regard to each particular set of terms—the Parties will negotiate any further refinement or narrowing of the same, if needed, once documents have been collected and initially analyzed, which has not yet been able to occur. For good cause, any terms still in dispute after collection, analysis, and meet and confers can be presented to the Court for resolution.

2. Standalone Terms

- a) The standalone terms shall remain on the standalone terms list denominated above, but the Parties will negotiate any further refinement or narrowing of these search terms, if needed, once documents have been collected and initially analyzed, which has not yet been able to occur. For good cause, any terms still in dispute after collection, analysis, and meet and confers can be presented to the Court for resolution.
- b) The following terms (1) when used against data of custodians working only at a particular facility would be run as standalone terms; and (2) when used against data of custodians in management over more than one facility would be run with <term> AND (<Drug Name> OR <Solvents> OR <Facility Name>), but can be tested and refined further to be <term> AND <facility name> AND (<Drug Name> OR (<Solvents> AND NOT <other drug names>)) if needed:

- i. EIR or “establishment inspection report”
- ii. OAI or “official action indicated”
- iii. “voluntary action indicated”
- iv. (Form 483) or (Form /3 483) or (483 /3 letter) or (483 /3 warn*) or (704 pre/3 b)

The Parties currently understand that the following custodians exercised management duties over multiple facilities:

1. Govindarajan Narayanan
2. Ram Mohan A Rao
3. Dasarathi
4. Srinivas K. Rama
5. Sudhakar Reddy Mandepudi
6. C.V. Satyendranath
7. R. Nagaraju
8. Subramanyam Maddala

The Parties agree that, should new evidence demonstrate that any of these individuals did not exercise management duties, then they will confer in good faith to discuss revising the list accordingly.

3. Manufacturing, Medical Conditions, Economic Terms, Entities

- a) The search string for these primary terms categories shall be: <Term> AND (<Drug Name> OR (<Solvents> AND NOT <other drug names>)) where <other drug names> will be an agreed to list of the names of each other non-nitrosamine-containing drug manufactured by the defendant running the modifiers. The Parties agree to the list given at (6) below;
- b) The Parties will negotiate any further refinement or narrowing of these search terms, if needed, once documents have been collected and initially analyzed, which has not yet been able to occur. For good cause, any terms still in dispute after collection, analysis, and meet and confers can be presented to the Court for resolution.

4. QA-Testing, cGMP, and Regulatory

- a) The search string for these shall be: <Term> AND (<Drug Name> OR (<Solvents> AND NOT <other drug names>) OR [other categories of modifiers]), using the agreed list at (6) below as the <other drug names>;
- b) The Parties will negotiate any further refinement or narrowing of these search terms, if needed, once documents have been collected and initially analyzed, which has not yet been able to occur. For good cause, any terms still in dispute after collection, analysis, and meet and confers can be presented to the Court for resolution.

5. List of <Other Drug Names>

a) As described above, certain strings will include a list of other, non-irbesartan drugs manufactured by the defendant. Here, the Parties agree that list will consist of the following drugs:

1. Abacavir
2. Acetaminophen
3. Acyclovir
4. Afirmelle
5. Alendronate
6. Alprazolam
7. Ambrisentan
8. Aminocaproic
9. Amiodarone
10. Amlodipine
11. Amox
12. Amoxicillin
13. Amphetamine
14. Anastrozole
15. APAP
16. Apixaban
17. Aprimilast
18. Aripiprazole
19. Armodafinil
20. Atazanavir
21. Atenolol
22. Aurovela
23. Azelastine
24. Azithromycin
25. Baclofen
26. Benazepril
27. Benzydryl
28. Bisoprolol
29. Buspirone
30. Butalbital
31. Caffeine
32. Capecitabine
33. Carbidopa
34. Carmustine
35. Carvedilol
36. Cefadroxil
37. Cefdinir
38. Cefixime

39. Cefpodoxime
40. Cefprozil
41. Cefuroxime
42. Celecoxib
43. Cephalexin
44. Cevimeline
45. Cinacalcet
46. Ciprofloxacin
47. Citalopram
48. Clarithromycin
49. Clavulanate
50. Clindamycin
51. Clobazam
52. Clomipramine
53. Clonazepam
54. Clopidogrel
55. Clorazepate
56. Clozapine
57. Codeine
58. Colchicine
59. Cyclobenzaprine
60. Dalfampridine
61. Desogestrel
62. Dextroamphetamine
63. Dicloxacillin
64. Dicyclomine
65. Digoxin
66. Dimethyl Fumarate
67. Divalproex
68. Dofetilide
69. Dorzolamide
70. Doxepin
71. Drospirenone
72. Drospirenone
73. Droxidopa
74. Duloxetine
75. Dutasteride
76. Efavirenz
77. Eletriptan
78. Emtricitabin
79. Emzabh
80. Entacapone
81. Entecavir
82. Erbumine
83. Erlotinib
84. Escitalopram

85. Esomeprazole
86. Estradiol
87. Eszopiclone
88. Ethinyl
89. Exemestane
90. Ezetimibe
91. Famotidine
92. Fenofibrate
93. Finasteride
94. Flecainide Acetate
95. Fluconazole
96. Flucytosine
97. Fluoxetine
98. Fosinopril
99. FREYALTA
100. Gabapentin
101. Galantamine
102. Ganciclovir
103. Gemfibrozil
104. Glipizide
105. Glyburide
106. Glycopyrrolate
107. HYCD
108. Hydrochlorothiazide
109. Hydrocodone
110. Hydromorphone
111. Hydroxyzine
112. Ibandronate
113. Ibuprofen
114. Iclevia
115. Imatinib
116. Incassia
117. Isosorbide
118. Lacosamide
119. Lamivudine
120. Lamotrigine
121. Lansoprazole
122. Leflunomide
123. Lenalidomide
124. Letrozole
125. Levetiracetam
126. Levodopa
127. Levofloxacin
128. Levonorgestrel
129. Loperamide
130. Lopinavir

131. Lorazepam
132. Lo-Zumandimine
133. Lurasidone
134. Medoxomil
135. Memantine
136. Meropenem
137. Mesalamine
138. Methadone
139. Methenamine
140. Methotrexate
141. Metoprolol
142. Midodrine
143. Mili
144. Minocycline
145. Mirtazapine
146. Modafinil
147. Montelukast
148. Moxifloxacin
149. Naproxen
150. Nevirapine
151. Niacin
152. Nifedipine
153. Nitrofurantoin
154. Norethindrone
155. Norgestimate
156. Nylia
157. Olanzapine
158. Olopatadine
159. Omeprazole
160. Ondansetron
161. Oxycodone
162. Oxymorphone
163. Pantoprazole
164. Paricalcitol
165. Paroxetine
166. Penicillin
167. Perindopril
168. Phentermine
169. Phenytoin
170. Pilocarpine
171. Pioglitazone
172. Potassium Chloride
173. Prasugrel
174. Prazosin
175. Prednisolone
176. Pregabalin

177.	Progesterone
178.	Propafenone
179.	Pyrimethamine
180.	Quetiapine
181.	Quinapril
182.	Rabeprazole
183.	Ramipril
184.	Ranolazine
185.	Repaglinide
186.	Ribavarin
187.	Ribavirin
188.	Risedronate
189.	Ritonavir
190.	Rivaroxaban
191.	Rivastigmine
192.	Rizatriptan
193.	Roflumilast
194.	Rosuvastatin
195.	Rufinamide
196.	Sertraline
197.	Sevelamer
198.	Sildenafil
199.	Silodosin
200.	Simethicone
201.	Simliya
202.	Simvastatin
203.	SMX/TMP
204.	Solifenacin
205.	Sulbactam
206.	Sumatriptan
207.	Tadalafil
208.	Tamoxifen
209.	Tamsulosin
210.	Tenofovir
211.	Terbinafine
212.	Timolol Maleate
213.	Tizanidine
214.	Torsemide
215.	Tramadol
216.	Trazodone
217.	Tri-Lo-Mili
218.	Ursodiol
219.	Valacyclovir
220.	Valganciclovir
221.	Venlafaxine
222.	Vigabatrin

- 223. Voriconazole
- 224. Zaleplon
- 225. Zidovudine
- 226. Ziprasidone
- 227. Zolpidem
- 228. Zumandimine